Jefferies Says No Changes to Ests on Amgen (AMGN) Amid Parsabiv CRL; Affirms at 'Buy'

Jefferies affirms Amgen (Nasdaq: AMGN) with a Buy rating and $198 price target following receipt of FDA CRL on Parsabiv.

The firm commented, On positive Ph3 data, FDA approval of Parsabiv for treatment of secondary hyperparathyroidism was largely expected. Details of the CRL is undisclosed. While we can't accurately forecast timing of potential approval, as we've assumed a launch in 2017 (~$500M in 2022 sales vs. cons. $575M), at present we're not changing our estimates. Parsabiv represents a small part of our current valuation for Amgen (NPV of ~$2/sh on 50% probability-adjusted, ~1% of our PT of $198).

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

You May Also Be Interested In

• Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
• Amgen (AMGN) PT Lowered to $284 at UBS
• HSBC Upgrades Topdanmark (TOP:DC) (TPDKY) to Hold